Compare iShares MSCI South Africa ETF (EZA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Africa ETF vs TG Therapeutics Inc — how do they compare? iShares MSCI South Africa ETF trades at $62.85, while TG Therapeutics Inc trades at $54.82 (market cap $8.64B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, iShares MSCI South Africa ETF nearer its low. Which is the better fit depends on your goals.
| EZA | TGTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $81.60 | $59.06 |
52-Week Low | $53.05 | $26.39 |
Market Cap | — | $8.64B |
Enterprise Value | — | $8.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EZA is trading at $62.83, down 0.98% on the day, with a bearish technical outlook indicated by moving averages and overall momentum. The stock shows neutral oscillator readings but faces selling pressure according to ADX indicators. Recent corporate actions include a $1.43 dividend scheduled for June 2026, providing some income appeal despite current technical weakness.
The stock faces headwinds from bearish technical signals while lacking current fundamental data for comprehensive analysis. Investment opportunity exists through the upcoming dividend, but requires monitoring of earnings reports and financial metrics once available. Key risks include market volatility and the need for updated financial disclosures to assess true valuation.
TG Therapeutics (TGTX) trades at $55.19, up 0.55% on the day, with a bullish technical signal from moving averages. The company shows strong profitability with a 65.95% net income margin and 112.6% ROE, though recent quarterly EPS has missed expectations. Positive clinical trial news for Briumvi in multiple sclerosis and schizophrenia is driving investor optimism and media coverage.
The outlook is supported by robust revenue growth and pipeline expansion, but risks include clinical trial execution and recent earnings volatility. Analysts are predominantly bullish with an 84.6% buy rating, though the consensus price target of $48.50 sits below the current price, suggesting potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
